Non-medullary thyroid Carconoma (NMTC)
Conditions
Brief summary
The number and percentage of subjects in whom there is reinduction of RaI uptake in RaI refractory target lesions. This will be assessed using RaI scintigraphy.
Detailed description
The proportion of subjects with a favorable response to RaI treatment after 6 months, according to RECIST criteria., Biochemical response to RaI treatment after 6 months, measured by thyroglobulin (TG)., Toxicity assessment using CTAE criteria v4.0., Quality of life using EORTC QLQ-C30., o Correlations between molecular pattern in pre-treatment biopsies (if available) and other study endpoints.
Interventions
DRUGLanoxin 125
DRUGtabletten 0
DRUG125 mg
DRUGSodium Iodide (I123) Injection
DRUGoplossing voor injectie 37 MBq/ml
Sponsors
Stichting Radboud University Medical Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number and percentage of subjects in whom there is reinduction of RaI uptake in RaI refractory target lesions. This will be assessed using RaI scintigraphy. | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of subjects with a favorable response to RaI treatment after 6 months, according to RECIST criteria., Biochemical response to RaI treatment after 6 months, measured by thyroglobulin (TG)., Toxicity assessment using CTAE criteria v4.0., Quality of life using EORTC QLQ-C30., o Correlations between molecular pattern in pre-treatment biopsies (if available) and other study endpoints. | — |
Countries
Netherlands
Outcome results
None listed